Recommendations for the use of clinical outcome assessments in rare disease drug development
Olalekan Lee Aiyegbusi(Patient-Centered Outcomes Research Institute), Steven Blackburn(National Institute for Health and Care Research), Volker Straub(Newcastle upon Tyne Hospitals NHS Foundation Trust), Victoria Hedley(Newcastle University), Samantha Cruz Rivera(University of Birmingham), Christian Griffiths(National Institute for Health and Care Excellence), Lindsey Murray(Health Outcomes Solutions (United States)), John Devin Peipert(Northwestern University), Michael W. Clarke(The University of Western Australia), Molly McFatrich(Duke University), Mel Dixon(Centre for Life), Ameeta Retzer(National Institute for Health and Care Research), Martin R. Higgs(University of Zurich), Brooke M. Currie(Health Outcomes Solutions (United States)), James Ennis(Centre for Life), Khadija Rantell, Ramona Moldovan(University of Manchester), Robert Muni‐Lofra(Newcastle upon Tyne Hospitals NHS Foundation Trust), Asha Hareendran(Pfizer (United States)), Onyekachukwu A. Illoh(United States Food and Drug Administration), Laura Wyatt(University of Nottingham), Hafiz Oko-osi(BioMarin (United States)), Christopher McCabe(University of Leeds), Louise Oni(University of Liverpool), Simon Gates(Oxford Brookes University), Fez Awan(Centre for Life), Prof Lucinda Billingham(Cancer Research UK Clinical Trials Unit), Noleen K.; id_orcid 0000-0002-8542-7665 McCorry(Queen's University Belfast), Blánaid Hicks, Timothy G.; id_orcid 0000-0002-6873-0750 Barrett(Birmingham City University), Melanie J. Calvert(Cancer Research UK Clinical Trials Unit), Amy Jayne McKnight(Queen's University Belfast), Melanie Duddridge(Centre for Life), Solomon Alexis(University of East London), Kate M. Pritchard(Centre for Life), Christine Collins(Centre for Life), Steven P. Lister(UCB Pharma (United Kingdom)), David Jones, Sarah Greenwell(Centre for Life), Hayley Comins, Fiona McLaughlin(Centre for Life), Matthew Hosken, Daniel J. O'Connor(Association of the British Pharmaceutical Industry), Sarah Scullion, Tom Bailey(AstraZeneca (Singapore)), Linda Fred(Centre for Life), Kerry Leeson-Beevers(Synome (United Kingdom)), Rosaline Callaghan(Centre for Life), Amber R. Hart, Krishna Letchemanan(AstraZeneca (Singapore))
Cited by 0
Related Papers
Interventions for preventing falls in older people living in the community
|Cochrane Database of Systematic Reviews|2012|3.9k
Midwife-led continuity models versus other models of care for childbearing women
|Cochrane Database of Systematic Reviews|2013|1.2k
Continuous support for women during childbirth
|Cochrane Database of Systematic Reviews|2012|1.2k
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension
|Nature Medicine|2020|1.2k
Symptoms, complications and management of long COVID: a review
|Journal of the Royal Society of Medicine|2021|978